Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming.

Saved in:
Bibliographic Details
Title: Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming.
Authors: Philbrook P; Department of Genetics, Louisiana State University Health Sciences Center, New Orleans, Louisiana.; LSU LCMC Health Cancer Center, Louisiana State University Health Sciences Center, New Orleans, Louisiana., Dean MJ; LSU LCMC Health Cancer Center, Louisiana State University Health Sciences Center, New Orleans, Louisiana.; Department of Interdisciplinary Oncology, Louisiana State University Health Sciences Center, New Orleans, Louisiana., Sanchez-Pino MD; LSU LCMC Health Cancer Center, Louisiana State University Health Sciences Center, New Orleans, Louisiana.; Department of Interdisciplinary Oncology, Louisiana State University Health Sciences Center, New Orleans, Louisiana., Zheng LQ; LSU LCMC Health Cancer Center, Louisiana State University Health Sciences Center, New Orleans, Louisiana.; Department of Interdisciplinary Oncology, Louisiana State University Health Sciences Center, New Orleans, Louisiana., Zabaleta J; LSU LCMC Health Cancer Center, Louisiana State University Health Sciences Center, New Orleans, Louisiana.; Department of Pediatrics, Louisiana State University Health Sciences Center, New Orleans, Louisiana., Vázquez-Martínez JA; Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Chang D; Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Mandula JK; Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Shaw TI; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Wyczechowska D; LSU LCMC Health Cancer Center, Louisiana State University Health Sciences Center, New Orleans, Louisiana.; Department of Interdisciplinary Oncology, Louisiana State University Health Sciences Center, New Orleans, Louisiana., Garai J; LSU LCMC Health Cancer Center, Louisiana State University Health Sciences Center, New Orleans, Louisiana.; Department of Interdisciplinary Oncology, Louisiana State University Health Sciences Center, New Orleans, Louisiana., Thylur Puttalingaiah R; LSU LCMC Health Cancer Center, Louisiana State University Health Sciences Center, New Orleans, Louisiana.; Department of Interdisciplinary Oncology, Louisiana State University Health Sciences Center, New Orleans, Louisiana., Mansouri A; Department of Interdisciplinary Oncology, Louisiana State University Health Sciences Center, New Orleans, Louisiana., Huang W; School of Veterinary Medicine, Louisiana State University, Baton Rouge, Louisiana., Das S; Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Chang S; Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Conejo-Garcia JR; Department of Integrated Immunobiology, Duke School of Medicine, Durham, North Carolina., Rodriguez PC; Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Ochoa AC; LSU LCMC Health Cancer Center, Louisiana State University Health Sciences Center, New Orleans, Louisiana.; Department of Interdisciplinary Oncology, Louisiana State University Health Sciences Center, New Orleans, Louisiana.
Source: Cancer immunology research [Cancer Immunol Res] 2026 Apr 02; Vol. 14 (4), pp. 640-657.
Publication Type: Journal Article
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101614637 Publication Model: Print Cited Medium: Internet ISSN: 2326-6074 (Electronic) Linking ISSN: 23266066 NLM ISO Abbreviation: Cancer Immunol Res Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2326-6074
DOI:10.1158/2326-6066.CIR-25-0695